New scan could spot hidden prostate cancer spread

NCT ID NCT05520255

Recruiting now Diagnosis Sponsor: University of Alberta Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 3 study is testing a radioactive tracer called 18F-PSMA-1007 for PET/CT scans in 2800 men with prostate cancer. The goal is to see if it can safely and accurately detect cancer that has spread, especially in men with rising PSA levels after treatment. Participants will be monitored for side effects right after injection and up to a week later.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-PSMA-1007 (a radioactive tracer for PET/CT imaging)
What this could lead to: If successful, this could give doctors a more accurate way to see where prostate cancer has spread, helping guide treatment decisions.
What could go wrong: This is still an investigational tracer, and the study focuses on imaging accuracy and safety, not treatment. It may not prove better than existing scans.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

University of Alberta
RECRUITING

Edmonton, Alberta, T6G 2R3, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.